Literature DB >> 22104964

Transforming growth factor-β is required for vasculogenic mimicry formation in glioma cell line U251MG.

Gengqiang Ling1, Shiyong Wang, Zhenhua Song, Xinlin Sun, Yijing Liu, Xiaodan Jiang, Yingqian Cai, Mouxuan Du, Yiquan Ke.   

Abstract

Both vasculogenic mimicry (VM) and transforming growth factor-β (TGFβ) are positively correlated with malignancy in glioma. Accordingly, we supposed that TGFβ might be related with VM, and aimed to detect whether TGFβ could influence VM formation in two glioma cell lines U251MG and SHG44, which were different in malignancy. We found that the VM-positive U251MG had a significantly higher TGFβ expression than the VM-negative SHG44. Downregulating TGFβ in U251MG by RNAi technology resulted in a significantly impaired VM formation, which could be rescued by rhTGFβ. However, adding rhTGFβ could not induce VM in SHG44. To investigate the possible mechanism, we detected the changes of some VM-related genes including EphA2, VE-cadherin, MMP-2, MMP-9, MT1-MMP and LAMC2 by RT-PCR and found that MT1-MMP transcript was affected by TGFβ expression. Gelatin zymography showed a declined MMP-2 activity in the TGFβ-inhibited cells. Further studies showed that MT1-MMP inhibition impaired VM formation in U251MG. Moreover, TGFβ induced MT1-MMP expression and VM formation in a dose-dependent manner. These findings indicated us that TGFβ was required for VM formation in U251MG. MT1-MMP was correlated with TGFβ-induced VM formation. Thus, TGFβ might be a potential target for VM inhibition in glioma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22104964      PMCID: PMC3280916          DOI: 10.4161/cbt.12.11.18155

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  46 in total

Review 1.  Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.

Authors:  R S Kerbel; J Yu; J Tran; S Man; A Viloria-Petit; G Klement; B L Coomber; J Rak
Journal:  Cancer Metastasis Rev       Date:  2001       Impact factor: 9.264

Review 2.  Membrane-type matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion.

Authors:  H L Fillmore; T E VanMeter; W C Broaddus
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

3.  Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2).

Authors:  A R Hess; E A Seftor; L M Gardner; K Carles-Kinch; G B Schneider; R E Seftor; M S Kinch; M J Hendrix
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

4.  Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry.

Authors:  M J Hendrix; E A Seftor; P S Meltzer; L M Gardner; A R Hess; D A Kirschmann; G C Schatteman; R E Seftor
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

5.  Molecular determinants of ovarian cancer plasticity.

Authors:  A K Sood; E A Seftor; M S Fletcher; L M Gardner; P M Heidger; R E Buller; R E Seftor; M J Hendrix
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

6.  Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma.

Authors:  R E Seftor; E A Seftor; N Koshikawa; P S Meltzer; L M Gardner; M Bilban; W G Stetler-Stevenson; V Quaranta; M J Hendrix
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

7.  Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry.

Authors:  Navesh Sharma; Richard E B Seftor; Elisabeth A Seftor; Lynn M Gruman; Paul M Heidger; Michael B Cohen; David M Lubaroff; Mary J C Hendrix
Journal:  Prostate       Date:  2002-02-15       Impact factor: 4.104

8.  Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer.

Authors:  K Shirakawa; H Tsuda; Y Heike; K Kato; R Asada; M Inomata; H Sasaki; F Kasumi; M Yoshimoto; T Iwanaga; F Konishi; M Terada; H Wakasugi
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

9.  Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma.

Authors:  C Kjellman; S P Olofsson; O Hansson; T Von Schantz; M Lindvall; I Nilsson; L G Salford; H O Sjögren; B Widegren
Journal:  Int J Cancer       Date:  2000-05-20       Impact factor: 7.396

10.  Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism.

Authors:  N A Bhowmick; M Ghiassi; A Bakin; M Aakre; C A Lundquist; M E Engel; C L Arteaga; H L Moses
Journal:  Mol Biol Cell       Date:  2001-01       Impact factor: 4.138

View more
  14 in total

1.  Orchestrated expression of vasculogenic mimicry and laminin-5γ2 is an independent prognostic marker in oral squamous cell carcinoma.

Authors:  Depanwita Saha; Debarpan Mitra; Neyaz Alam; Sagar Sen; Saunak Mitra Mustafi; Syamsundar Mandal; Biswanath Majumder; Nabendu Murmu
Journal:  Int J Exp Pathol       Date:  2022-02-16       Impact factor: 1.925

2.  Prrx1 promotes resistance to temozolomide by upregulating ABCC1 and inducing vasculogenic mimicry in glioma.

Authors:  Zetao Chen; Yujie Zhang; Yihong Chen; Wanmei Lin; Yuxuan Zhang; Guixing Cai; Xinlin Sun; Kehong Zheng; Jie He; Tianjing Ai; Jihui Wang; Liang Zhao; Yiquan Ke
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

3.  The up-regulation of cysteine-rich protein 61 induced by transforming growth factor beta enhances osteosarcoma cell migration.

Authors:  Jun Chen; Yang Song; Jing Yang; Li Gong; Peng Zhao; Yong Zhang; Haichuan Su
Journal:  Mol Cell Biochem       Date:  2013-09-14       Impact factor: 3.396

Review 4.  Vascular mimicry: changing the therapeutic paradigms in cancer.

Authors:  Nazila Fathi Maroufi; Sina Taefehshokr; Mohammad-Reza Rashidi; Nima Taefehshokr; Mahdieh Khoshakhlagh; Alireza Isazadeh; Narmin Mokarizadeh; Behzad Baradaran; Mohammad Nouri
Journal:  Mol Biol Rep       Date:  2020-05-18       Impact factor: 2.316

5.  Glioblastoma vasculogenic mimicry: signaling pathways progression and potential anti-angiogenesis targets.

Authors:  Jin-Ming Mao; Jing Liu; Geng Guo; Xing-Gang Mao; Chang-Xin Li
Journal:  Biomark Res       Date:  2015-04-18

6.  Endothelial-like malignant glioma cells in dynamic three dimensional culture identifies a role for VEGF and FGFR in a tumor-derived angiogenic response.

Authors:  Stuart J Smith; Jennifer H Ward; Christopher Tan; Richard G Grundy; Ruman Rahman
Journal:  Oncotarget       Date:  2015-09-08

7.  Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase / ERK-MMP-laminin5γ2 signaling pathway.

Authors:  Xiao Liu; Ji-Hui Wang; Shun Li; Lin-Lin Li; Min Huang; Yong-Hong Zhang; Yang Liu; Yuan-Tao Yang; Rui Ding; Yi-Quan Ke
Journal:  Cancer Sci       Date:  2015-06-18       Impact factor: 6.716

8.  Dual Receptor Recognizing Cell Penetrating Peptide for Selective Targeting, Efficient Intratumoral Diffusion and Synthesized Anti-Glioma Therapy.

Authors:  Yayuan Liu; Ling Mei; Chaoqun Xu; Qianwen Yu; Kairong Shi; Li Zhang; Yang Wang; Qianyu Zhang; Huile Gao; Zhirong Zhang; Qin He
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

9.  All-trans retinoic acid impairs the vasculogenic mimicry formation ability of U87 stem-like cells through promoting differentiation.

Authors:  Geng-Qiang Ling; Yi-Jing Liu; Yi-Quan Ke; Lei Chen; Xiao-Dan Jiang; Chuan-Lu Jiang; Wei Ye
Journal:  Mol Med Rep       Date:  2015-03-06       Impact factor: 2.952

10.  Curcumin inhibits vasculogenic mimicry through the downregulation of erythropoietin-producing hepatocellular carcinoma-A2, phosphoinositide 3-kinase and matrix metalloproteinase-2.

Authors:  Yiming Liang; Min Huang; Jianwen Li; Xinlin Sun; Xiaodan Jiang; Liangping Li; Yiquan Ke
Journal:  Oncol Lett       Date:  2014-07-31       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.